Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

EZH2-Mediated Methylation Regulates JARID2 Protein Stability in Normal and Neoplastic Hematopoiesis

Hassan Bjeije, Wentao Han, Hamza Celik, Yanan Li, Michael P. Rettig, Andrew L Young, Saranajith Dunuwille, Nancy Issa, Wei Yang, Jeffrey A. Magee, Grant A Challen

Blood (2024) 144 (Supplement 1): 628.

https://doi.org/10.1182/blood-2024-202827

Published: 2024

Journal Articles

Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Stephanie Christ, Feng Gao, Hailey Sappington, Sana Saif Ur Rehman, Suzanne R. Thibodeaux, Ella Sorani, Allison A. King, John F. DiPersio

Blood (2024) 144 (Supplement 1): 145.

https://doi.org/10.1182/blood-2024-193210

Published: 2024

Journal Articles

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

Blood (2024) 144 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2024-201998

Published: 2024

Journal Articles

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Michael H. Kramer, Neha Mehta-Shah, Michael P. Rettig, Katherine Stricker, Melinda Harding, Feng Gao, Brett Ramsey, Peter Westervelt, Jan K Davidson-Moncada, Armin Ghobadi, John F. DiPersio, Geoffrey L. Uy

Blood (2024) 144 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2024-200809

Published: 2024

Journal Articles

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Blood (2024) 144 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2024-202005

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

In Vivo and Ex Vivo Expansion of Functional Human Repopulating Cells through JARID2 Inhibition

Wentao Han, Hassan Bjeije, Hamza Celik, Michael P. Rettig, Yanan Li, Andrew L Young, Christine RC Zhang, Infencia Xavier Raj, Saranajith Dunuwille, Grant A Challen

Blood (2024) 144 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2024-211397

Published: 2024

Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio

Blood (2023) 142 (Supplement 1): 764.

https://doi.org/10.1182/blood-2023-181087

Published: 2023

Journal Articles

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2023) 142 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2023-181174

Published: 2023

Journal Articles

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Michael Slade, Michael P. Rettig, Zachary David Crees, Neha Mehta-Shah, Todd A Fehniger, Amanda F Cashen, Iskra Pusic, Geoffrey L Uy, Peter Westervelt, John DiPersio, Armin Ghobadi

Blood (2023) 142 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2023-172439

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Rawan Faramand, Ryan J Mattison, Bhagirathbhai Dholaria, Michael P. Rettig, Ken Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen McNulty, Matt L. Cooper, Jan Davidson-Moncada, John F. DiPersio

Blood (2023) 142 (Supplement 1): 770.

https://doi.org/10.1182/blood-2023-178723

Published: 2023

Journal Articles

Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo

Julie O'Neal, Julie K. Ritchey, Susan Gladney, Gabriel J. Haas, Ramzi Abboud, Michael P. Rettig, Cedric Bruges, Linda Eissenberg, John F. DiPersio

Blood (2023) 142 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2023-183025

Published: 2023

Journal Articles

Identifying Surface Protein Markers for AML Immunotherapy

Omar M. Ibrahim, Michael P. Rettig, Ezhilarasi Chendamarai, Reyka G. Jayasinghe, Li Ding, John DiPersio

Blood (2023) 142 (Supplement 1): 6809.

https://doi.org/10.1182/blood-2023-187831

Published: 2023

Journal Articles

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio

Blood (2023) 141 (14): 1718–1723.

https://doi.org/10.1182/blood.2022017795

Published: 2023

Includes: Supplemental data

Journal Articles

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 4477–4478.

https://doi.org/10.1182/blood-2022-159734

Published: 2022

Journal Articles

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Peter Ruminski, Abi Vainstein, Ella Sorani, Allison A. King, John F. DiPersio

Blood (2022) 140 (Supplement 1): 10432–10433.

https://doi.org/10.1182/blood-2022-165454

Published: 2022

Journal Articles

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Ezhilarasi Chendamarai, Julie K. Ritchey, Leah Gehrs, Michael P. Rettig, Sai Mukund Ramakrishnan, Christopher A Miller, George Cox, Lana Anderson, Timothy J Ley, John F. DiPersio

Blood (2022) 140 (Supplement 1): 7345–7346.

https://doi.org/10.1182/blood-2022-167415

Published: 2022

Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio

Blood (2022) 140 (Supplement 1): 8795–8796.

https://doi.org/10.1182/blood-2022-156943

Published: 2022

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

EZH2-Mediated Methylation Regulates JARID2 Protein Stability in Normal and Neoplastic Hematopoiesis

Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

In Vivo and Ex Vivo Expansion of Functional Human Repopulating Cells through JARID2 Inhibition

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo

Identifying Surface Protein Markers for AML Immunotherapy

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only